The present invention is concerned with dispersible compositions comprising bedaquiline fumarate as an active ingredient. Such compositions are useful in the treatment of tuberculosis and their inherent dispersibility properties lend themselves to be useful in particular amongst the pediatric or geriatric population.

Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

In an example of a three-dimensional (3D) printing method for forming a pharmaceutical tablet, build material granules are applied. Each of the build material granules includes a plurality of excipient particles, wherein at least one of the plurality of excipient particles is a latent binder. Pressure is applied to the build material granules. An activation solvent is selectively applied on at least a portion of the pressed build material granules. An active pharmaceutical ingredient formulation including an active pharmaceutical ingredient is selectively applied on the at least the portion of the pressed build material granules. The activation solvent is evaporated.

The present invention relates to a composite agent comprising polmacoxib and pregabalin. The present invention relates to a pharmaceutical composition and a drug or pain reliever, which each comprise the two active ingredients of polmacoxib and pregabalin and, more particularly, to a drug or pain reliever for treatment of moderately severe, acute, chronic, or neuropathic pain attributed to inflammation and various factors, an effect thereof, and a use thereof.

Disclosed herein are methods for preparing modified starches, and uses thereof, and relates to the technical field of starch preparation; modifying a gelatinized starch suspension with β-amylase; after inactivating the β-amylase, further modifying with a branching enzyme, after inactivating the branching enzyme, further modifying with pullulanase, after inactivating the pullulanase, precipitating a resulting enzymatic hydrolysate with an alcohol to obtain precipitates; and drying the precipitates to obtain the modified starch. The methods disclosed a starch is modified remarkably, herein substantially increase the number of linear chains with a degree of polymerization DP6-11 in the starch chains and, thus, significantly increase the content of resistant starch in the modified starch—thereby facilitating the use in foods and medicaments.

Disclosed herein are pharmaceutical compositions having a mixture of at least one active agent and an ion exchange resin, such that the composition releases about 75% or more of the at least one active agent within about 1 hour as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at about 50 rpm in about 900 ml 0.1N HCl at about 37° C. and related methods. Also disclosed herein are pharmaceutical compositions having a mixture of a drug susceptible to abuse, a non-opioid analgesic and an ion exchange resin, the composition further including at least one gelling agent and related methods.

This invention relates to a novel anti-RNA virus, including anti-SARS-CoV-2 virus, pharmaceutical composition Avifavir in tablets or capsules containing less than 50 wt % of micronized favipiravir, with the remainder being excipients.

Medicinal product Avifavir for the prevention and treatment of COVID-19 coronaviral disease, said medicinal product being a pharmaceutical composition in coated tablets containing 200 mg, 300 mg, 400 mg, or 600 mg of micronized favipiravir (less than 40-45%) with a particle size of less than 60 μm, with the remainder being excipients.

The present invention is related to the use of thromboxane A2 receptor antagonists (e.g., 3-[2-[[(1S,2R,3S,4R)-3-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]propanoic acid (Ifetroban), or one, or a mixture of more than one pharmaceutically acceptable salts thereof) in the treatment of SARS-CoV-2 infection in humans, and pharmaceutical compositions for the same comprising thromboxane A2 receptor antagonists (e.g., ifetroban) in an effective amount to treat and/or prevent conditions resulting from such infection.

The present disclosure is directed to pharmaceutical compositions and to the use of such formulations in the treatment of diseases associated with a serotonin 5-HT.sub.2 receptor.

Intravesical drug delivery devices that include a device body, a number of solid drug tablets, and a retention frame. The device body includes a drug reservoir lumen and a retention frame lumen. The drug tablets is positioned in the drug reservoir lumen, and the retention frame is positioned in the retention frame lumen.